中华放射肿瘤学杂志
Monday, Apr. 7, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2020, Vol. 29 Issue (10): 855-858    DOI: 10.3760/cma.j.cn113030-20190805-00314
Abdominal Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Preliminary clinical observation of efficacy and safety of stereotactic body radiation therapy in combination with targeted therapy for metastatic renal cell carcinoma
Liu Yang1, Dong Pei2, Huang Sijuan1, Cao Wufei1, Liu Boji1, Lin Maosheng1, Jiang Xiaobo1, Lin Chengguang1, Liu Zhuowei2, Han Hui2, Li Yonghong2, Liu Mengzhong1, Zhou Fangjian2, He Liru1
1Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China;
2Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Objective To evaluate the preliminary clinical efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with targeted therapy for metastatic renal cell carcinoma (mRCC). Methods Clinical data of 58 patients with mRCC who were treated with SBRT in combination with targeted therapy in Sun Yat-sen University Cancer Center from June 2013 to December 2018 were retrospectively analyzed. Among them, 79.3% patients were classified as intermediate or high risk according to International Metastatic Renal Cell Carcinoma Database Consortium Criteria. The median biologically equivalent dose (BED) was 147 Gy (67 to 238 Gy). Results Overall, 32, 13, 7, 5 and 1 patients received SBRT for 1, 2, 3, 4 and 6 metastatic sites (105 lesions) and 71.4% of them were bone lesions. Targeted therapy was continued during SBRT. With a median follow-up of 9.4 months (range 2.7 to 40.1 months), 18 patients died. The 1-year local control rate was 97.4%. The 1-year progression-free survival was 50.3%. The 1-and 2-year overall survival was 72% and 53%. Approximately 85% patients experienced pain relief after SBRT. Patients who achieved complete or partial response after SBRT obtained better overall survival than those with stable disease or disease progression (1-year overall survival:83% vs. 48%,P=0.021). In the whole cohort, 6 cases developed Grade Ⅲ adverse events, 4 of which were Grade Ⅲ myelosuppression, 1 case of Grade Ⅲ neuropathy and 1 case of radiation-induced skin injury. Conclusion Preliminary study reveals that combined use of targeted therapy and SBRT is an efficacious and safe treatment of advanced mRCC.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Liu Yang
Dong Pei
Huang Sijuan
Cao Wufei
Liu Boji
Lin Maosheng
Jiang Xiaobo
Lin Chengguang
Liu Zhuowei
Han Hui
Li Yonghong
Liu Mengzhong
Zhou Fangjian
He Liru
Key wordsNeoplasm metastasis, renal/targeted therapy      Neoplasm metastasis, renal/stereotactic body radiation therapy      Clinical efficacy      Safety     
Received: 05 August 2019     
Corresponding Authors: He Liru, Email:helir@sysucc.org.cn   
Cite this article:   
Liu Yang,Dong Pei,Huang Sijuan et al. Preliminary clinical observation of efficacy and safety of stereotactic body radiation therapy in combination with targeted therapy for metastatic renal cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 855-858.
Liu Yang,Dong Pei,Huang Sijuan et al. Preliminary clinical observation of efficacy and safety of stereotactic body radiation therapy in combination with targeted therapy for metastatic renal cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 855-858.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20190805-00314     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I10/855
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn